THERAPY DOSSIER · th-9ef4dcdac653

INCB3344

Drug · No confident ChEMBL match; CCR2 chemokine receptor antagonist (research tool)

Evidence & regulatory context

Mechanism: No confident ChEMBL match; CCR2 chemokine receptor antagonist (research tool)
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25999385 ↗2015Reported harm

Evidence That Ly6C(hi) Monocytes are Protective in Acute Ischemic Stroke by Promoting M2 Macrophage Polarization.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)C57Bl/6JMaleIntraperitoneal10, 30 or 100 mg/kg1 hour before ischaemia, and at 2 and 6 hours after ischaemia

Model: Middle cerebral artery occlusion for 1 hour followed by 23 hours of reperfusion

INCB3344 dose-dependently prevented the stroke-induced rise in Ly6C(hi) monocytes but worsened functional outcomes and increased infarct volume, with reduced M2 polarisation and increased peroxynitrite in macrophages, indicating these monocytes are protective.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…